We supply Erdafitinib API

We're pleased to offer Erdafitinib API, a potent and picky asset of fibroblast growth factor receptor( FGFR) used in the treatment of locally advanced or metastatic urothelial melanoma. Our product is of high quality and meets all necessary norms for pharmaceutical use. It's important to note that while it has shown promising results in clinical trials, it should only be administered under the supervision of a good healthcare professional. We're committed to furnishing our guests with the stylish possible service and quality products, and are confident that our Erdafitinib will meet your requirements.

What's Erdafitinib API?

Erdafitinib is a new drug that's designed to treat colorful forms of cancer, including urothelial melanoma. This drug is available in the form of an active pharmaceutical component( API), which is used in the product of final medicine products.

It works by widely targeting specific receptors in cancer cells, thereby inhibiting their growth and precluding them from spreading to other corridor of the body. This drug is largely effective against cancer cells that are resistant to conventional treatments, making it a precious addition to cancer treatment protocols.

One of its crucial advantages is its high selectivity and particularity, which means that it doesn't affect normal healthy cells, minimizing the side goods associated with traditional chemotherapy. also, this drug has shown promising results in clinical trials, demonstrating its eventuality as a important new armament in the fight against cancer.

It is manufactured to the loftiest norms of quality and safety, icing its chastity and energy. It's available in colorful forms and boluses to meet the requirements of different cases and treatment protocols.

In conclusion, it is an innovative and effective drug that offers new stopgap to cancer cases. Whether used as a standalone treatment or in combination with other curatives, this drug has the implicit to ameliorate patient issues and protract survival. Its high selectivity, low toxin, and proven efficacity make it a precious addition to the cancer treatment armamentarium.

Basic Information

Product Name: Erdafitinib (JNJ-42756493)

CAS: 1346242-81-6

MF:C25H30N6O2

MW:446.54

MDL No.:MFCD28502040

Melting point:136-140°C

Boiling point:662.3±55.0 °C(Predicted)

Density 1.20±0.1 g/cm3(Predicted)

Structural formula:

Application: Lab Research

Origin: China

Delivery Time: in stock

Technical Specification

Package: 1g; 10g; or according to your demands

Storage conditions: -20 ℃, protected from light and moisture, sealed and dry

Transportation conditions: 2-8 ℃ transportation

Shelf Life:24 months

Indication

Erdatinib is a kinase asset targeting FGFR, used to treat adult cases with locally advanced or metastatic urothelial melanoma. Cases with locally advanced or metastatic urothelial melanoma who witness complaint progression during or after platinum chemotherapy have FGFR3 or FGFR2 gene mutations, including those who suffer neoadjuvant or adjuvant platinum chemotherapy within 12 months.

The first target medicine for bladder cancer

In April 2019, FDA approved  Erdafitinib, the first approved targeted medicine for metastatic bladder cancer, for the treatment of locally advanced or metastatic bladder cancer grown-ups with complaint progression after platinum chemotherapy with FGFR3 or FGFR2 mutations. The BLC2001 clinical trial data, which was the base for blessing, showed that the ORR of 87 cases with bladder cancer with advanced FGFR gene mutation after treatment was32.2( CR2.3, PR29.9). lately, streamlined data showed that the ORR of 99 cases with bladder cancer with advanced FGFR gene mutation was 40( CR3, PR37), and the ORR of 22 cases with immunotherapy was as high as 59. The results were published in the New England Journal of Medicine!

Biological activity

Erdafitinib API( JNJ- 42756493) is an effective, picky, and orally biologically active visage fibroblast growth factor receptor FGFR asset with implicitanti-tumor exertion. Erdafitinib can also bind RET( c- RET), CSF- 1R, PDGFR- α/ PDGFR- β, FLT4, tackle( c- tackle), and VEGFR- 2 and induce cell apoptosis.

In vitro exploration

JNJ- 42756493 is an effective and orally active visage FGFR tyrosine kinase asset that has an IC50 in the low attention molar range for all members of the FGFR family( FGFR1- 4), with little effect on the exertion of VEGFR. In vitro, JNJ- 42756493 treatment redounded in reduced cell proliferation, increased apoptotic death, and dropped cell survival.

In vivo exploration

In vivo trials, treatment with JNJ- 42756493 delayed the growth of NCI- H716 excrescences, while when medicine treatment was withdrawn, the excrescence volume increased. JNJ- 42756493 has good medicine like parcels and is extensively distributed in lung, liver, and order apkins. At effective boluses, JNJ- 42756493 is well permitted, exhibits cure-dependentanti-tumor exertion, and has a pharmacological nonsupervisory effect on FGFR and its downstream pathway factors in excrescences.

Payment Term

Why Choose Xi'an Yihui?

Customer feedback

Xi'an Yihui certificates

Xi'an Yihui Factory & Warehouse

Where to buy?

In summary, as a professional Erdafitinib APImanufacturer, we have advanced technology, scale advantage, the best quality, rich production experience, and excellent services. These advantages will make it stand out in the market competition and win more customer trust and support. if you need JNJ- 42756493, pls feel free to contact us any time. we will reply you asap.

our contact information:

E-mail: sales@yihuipharm.com
Tel: 0086-29-89695240
WeChat or WhatsApp: 0086-17792415937